Ellen S. Yetzer

1046 FIRST-IN-MAN DEMONSTRATION OF POTENT ANTIVIRAL ACTIVITY WITH A NUCLEOSIDE POLYMERASE (R7128) AND PROTEASE (R7227/ITMN-191) INHIBITOR COMBINATION IN HCV: SAFETY, PHARMACOKINETICS, AND VIROLOGIC RESULTS FROM INFORM-1

Edward Gane, S. Roberts, Catherine Stedman et al. · Journal of Hepatology · 2009 · 63 citations

Medicine, Infectious Diseases, Pharmacology +14

Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection

Joseph J. Eron, Ellen S. Yetzer, Peter Ruane et al. · AIDS · 2000 · 62 citations

Pharmacy, Pharmacokinetics, Pharmacotherapy +17

1412 INTERFERON-FREE TREATMENT WITH A COMBINATION OF MERICITABINE AND DANOPREVIR/R WITH OR WITHOUT RIBAVIRIN IN TREATMENT-NAIVE HCV GENOTYPE 1-INFECTED PATIENTS

Edward Gane, Paul J. Pockros, Stefan Zeuzem et al. · Journal of Hepatology · 2012 · 55 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +10

Baseline factors prognostic of sustained virological response in patients with HIV–hepatitis C virus co-infection

Gregory J. Dore, Francesca J. Torriani, M. Rodríguez‐Torres et al. · AIDS · 2007 · 41 citations

Pharmacy, Infectious Diseases, Clinical Epidemiology +16

<scp>DAUPHINE</scp>: a randomized phase <scp>II</scp> study of danoprevir/ritonavir plus peginterferon alpha‐2a/ribavirin in <scp>HCV</scp> genotypes 1 or 4

Gregory T. Everson, Curtis Cooper, Christophe Hézode et al. · Liver International · 2014 · 30 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +15